Across TCGA pan-cancer cohorts, LYRM4 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LYRM4 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher LYRM4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LYRM4 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC, HNSC, and CCRCC are the cancer types where LYRM4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.878	0.526	.004	20	view →
HNSC	OS	Quartile	II,III,IV	0.818	0.966	.004	11	view →
CCRCC	DFS	Median	II,III,IV	0.449	0.756	.006	10	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: LYRM4 tumor-vs-normal RNA expression · all LYRM4 data types